Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

July 29, 2015

Introducing New Agents into the Standard of Care

Dr. S. Yosuf Zafar questions how to incorporate new agents into the standard of cancer care as many of these agents are both expensive and only useful for a small segment of patients.

March 31, 2015

Challenge of Sustainable Pricing Model

Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.